Indian Pharma Giants Bet on Ozempic Copy Amid Revenue Decline

CosmicTaco · 2025-02-19T10:46:55.901418+05:30

- Natco Pharma and Dr. Reddy's shift focus to weight-loss drug Ozempic's generic version to counter revenue drop from Revlimid. - Natco's shares fell 30% post weak Q3 earnings; Dr. Reddy's profits from Revlimid face future decline. - Both companies eye Semaglutide market, with Natco securing exclusivity and Dr. Reddy's planning launches in Canada and emerging markets. Source: [Mint](https://www.livemint.com/companies/latest-company-news-today-on-february-19-2025-live-updates-11739923221464.html), [Mint](https://www.livemint.com/companies/will-natco-and-dr-reddys-bet-on-weight-loss-drug-ozempics-copy-pay-off-11739886055094.html)

Natco Pharma and Dr. Reddy's shift focus to weight-loss drug Ozempic's generic version to counter revenue drop from Revlimid.
Natco's shares fell 30% post weak Q3 earnings; Dr. Reddy's profits from Revlimid face future decline.
Both companies eye Semaglutide market, with Natco securing exclusivity and Dr. Reddy's planning launches in Canada and emerging markets.

Source: Mint, Mint